| Literature DB >> 30021061 |
Olivier Sérée1,2, Mario Altieri2,3, Elodie Guillaume2, Rémy De Mil2,4, Thierry Lobbedez5, Philip Robinson6, Philippe Segol7, Ephrem Salamé8, Armand Abergel9, Olivier Boillot10, Filomena Conti11, Olivier Chazouillères12, Maryline Debette-Gratien13, Dominique Debray14, Géraldine Hery15, Sébastien Dharancy16, François Durand17, Christophe Duvoux18, Claire Francoz17, Jean Gugenheim19, Jean Hardwigsen20, Pauline Houssel-Debry21, Emmanuel Jacquemin22, Nassim Kamar23, Marianne Latournerie24, Pascal Lebray11, Vincent Leroy25, Alessandra Mazzola11, Martine Neau-Cransac26, Georges-Philippe Pageaux27, Sylvie Radenne28, Faouzi Saliba29, Didier Samuel29, Claire Vanlemmens30, Marie-Lorraine Woehl-Jaegle31, Guy Launoy2,4, Jérôme Dumortier10.
Abstract
De novo malignancies are one of the major late complications and causes of death after liver transplantation (LT). Using extensive data from the French national Agence de la Biomédecine database, the present study aimed to quantify the risk of solid organ de novo malignancies (excluding nonmelanoma skin cancers) after LT. The incidence of de novo malignancies among all LT patients between 1993 and 2012 was compared with that of the French population, standardized on age, sex, and calendar period (standardized incidence ratio; SIR). Among the 11,226 LT patients included in the study, 1200 de novo malignancies were diagnosed (10.7%). The risk of death was approximately 2 times higher in patients with de novo malignancy (48.8% versus 24.3%). The SIR for all de novo solid organ malignancies was 2.20 (95% confidence interval [CI], 2.08-2.33). The risk was higher in men (SIR = 2.23; 95% CI, 2.09-2.38) and in patients transplanted for alcoholic liver disease (ALD; SIR = 2.89; 95% CI, 2.68-3.11). The cancers with the highest excess risk were laryngeal (SIR = 7.57; 95% CI, 5.97-9.48), esophageal (SIR = 4.76; 95% CI, 3.56-6.24), lung (SIR = 2.56; 95% CI, 2.21-2.95), and lip-mouth-pharynx (SIR = 2.20; 95% CI, 1.72-2.77). In conclusion, LT recipients have an increased risk of de novo solid organ malignancies, and this is strongly related to ALD as a primary indication for LT.Entities:
Mesh:
Year: 2018 PMID: 30021061 DOI: 10.1002/lt.25310
Source DB: PubMed Journal: Liver Transpl ISSN: 1527-6465 Impact factor: 5.799